India’s Bioeconomy

India aims to achieve a $1.2 trillion bioeconomy by 2047, which will require capital-market innovation, regulatory modernization, and a strategic blend of technological and scientific innovation.

What is Bioeconomy?

According to the Food and Agriculture Organization (FAO), the bioeconomy involves:

• The production, utilization, and conservation of biological resources.

• Integration of knowledge, science, technology, and innovation to provide:

  • Information

  • Products

  • Processes

  • Services across all economic sectors.

Goal: Promote a sustainable economy while leveraging biological resources efficiently.

Status of India’s Bioeconomy

• Rapid Growth: The sector has expanded 16-fold in a decade, from $10 billion in 2014 to over $165 billion in 2024.

• Contribution to GDP: India’s bioeconomy contributes 4.25% to the national GDP, highlighting its growing significance in national development.

• Key Drivers:

  • Advances in biotechnology, pharmaceuticals, agriculture, and bioenergy.

  • A thriving startup ecosystem and government support.

• Ethanol Production:

  • India is the third-largest producer of blended ethanol.

  • Ethanol production has almost tripled in five years, supporting energy security and decarbonization efforts.

Key Sectors Driving India’s Bioeconomy

India’s bioeconomy is powered by multiple high-potential sectors that are driving innovation, economic growth, and sustainability.

1. Biopharma
India is already a global leader in generic drugs and vaccines. The country is now focusing on advanced therapeutics, including biologics, biosimilars, and personalized medicine, which can help India compete in the global pharmaceutical and biotechnology markets.

2. Agricultural Biotechnology
Innovations in crop genetics, biofertilizers, and precision farming are enabling enhanced food security and promoting sustainable agriculture practices. These developments are crucial for supporting India’s growing population while reducing environmental impacts.

3. Bioenergy and Biofuels
India is expanding production of bioethanol and biogas, which offer scalable alternatives to fossil fuels. These biofuels support the country’s clean energy transition and contribute to decarbonization efforts.

4. Industrial Biotechnology
The sector includes enzymes, bioplastics, and green chemicals, which serve as eco-friendly industrial inputs. These innovations reduce reliance on traditional chemical processes and promote sustainable manufacturing.

Potential Impact
By focusing on these sectors, India can develop thousands of deep-tech startups, become a global leader in mRNA, RNAi, gene therapy, biosimilars, and biologics, emerge as a preferred hub for clinical research and bio-manufacturing, generate millions of high-value jobs, and achieve a $1.2 trillion bioeconomy by 2047 under the BioE³ framework.

India’s Push for Expanding the Bioeconomic Architecture

BioE³ Policy
The BioE³ (Biotechnology for Economy, Environment, Employment) policy acts as a unifying strategy to propel India’s bioeconomy. It focuses on six key domains:

1. Bio-based chemicals

2. Functional foods

3. Carbon capture technologies

4. Precision biotherapeutics

5. Climate-smart agriculture

6. Marine and space bio-research

Other Key Measures
Several national initiatives complement the BioE³ policy:

• National Mission on Bioeconomy (2016) – Provides a strategic roadmap for biotechnology development.

• National Biopharma Mission – Accelerates innovation and manufacturing in biopharma.

• Bio-RIDE and BioNEST incubators – Support biotech startups and promote innovation ecosystems.

• Global Biofuels Alliance – Encourages international collaboration in biofuels.

• National Biological Data Centre (NBDC) – Serves as a central repository for biological data, facilitating research and development.

Hindrances to Achieving a $1.2 Trillion Bioeconomy by 2047

India’s ambition to become a $1.2 trillion bioeconomy faces multiple structural, regulatory, and infrastructural challenges:

1. Structural Bottlenecks

• India does not permit pre-revenue or research-stage biotech companies to list publicly.

• As a result:

  • Innovators rely heavily on private, risk-averse capital.

  • Valuations remain suppressed.

  • High-potential startups relocate abroad, seeking more supportive ecosystems.

2. Regulatory Inefficiencies

• Cumbersome approval processes for biotech products delay innovation and commercialization.

• Absence of a single-window clearance system creates uncertainty for startups and research trials.

• First-in-Human (FIH) trial approvals take months, and each trial phase requires a fresh Subject Expert Committee (SEC) review.

• CDSCO lacks scientific capacity to assess emerging modalities such as mRNA, CRISPR, CAR-T, and gene therapies.

3. Limited Capital Market Access

• Biotech startups struggle to raise early-stage and scale-up funding due to high R&D risks and long gestation periods.

• India lacks a robust biotech IPO pipeline, unlike the US and China, where public markets actively support biotech innovation.

4. Fragmented Innovation Ecosystem

• Weak industry-academia linkages hinder translational research and product development.

• Many innovations remain trapped in labs due to poor commercialization pathways and limited technology transfer infrastructure.

5. Inadequate Infrastructure

• Shortage of biomanufacturing facilities, especially for biologics, diagnostics, and advanced therapeutics.

6. Policy and Coordination Gaps

• Multiple ministries (Science & Technology, Health, Agriculture, Environment) operate in silos, leading to policy fragmentation.

• Absence of a centralized bioeconomy mission or roadmap with measurable milestones hampers strategic alignment.

Key Suggestions for Achieving a $1.2 Trillion Bioeconomy

1. Regulatory Reform

• India’s current drug-regulation system, led by CDSCO, is slow, fragmented, and bureaucratic.

• Even with capital access, innovation will stagnate without regulatory speed and scientific clarity.

2. Innovation & Biotech Board

• India urgently needs a dedicated listing board on NSE and BSE, modeled on NASDAQ, STAR, and Hong Kong’s Biotech Chapter.

• Benefits of such a platform:

  • Allow pre-revenue and research-stage biotech listings.

  • Enable IP-led companies to access patient capital.

  • Attract global investors to India’s science story.

  • Encourage domestic scaling instead of foreign migration.

3. Focus on Innovation

• A combination of capital-market reform and regulatory reform can drive innovation that powers global biotech leadership.

• Requires:

  • A dedicated Innovation & Biotech Board.

  • A science-led dual-agency regulatory system.

  • Strong institutional support for startups and research institutions.

Two-Pillar Regulatory Model for India

1. Empower ICMR for Scientific Review

   • Leverage ICMR’s research depth and ethical infrastructure for evaluating early-stage drugs, vaccines, diagnostics, and advanced biologics.

2. Position CDSCO as Licensing Authority

   • CDSCO should focus on final approvals, GMP compliance, site inspections, and pharmacovigilance.

Benefits of this model:

• Separation of scientific assessment (ICMR) and administrative licensing (CDSCO) can:

  • Reduce approval timelines.

  • Improve scientific rigour.

  • Reinforce investor confidence in India’s biotech ecosystem.

Conclusion

India stands at a decisive juncture in its journey toward becoming a global bioeconomy leader. The country already possesses world-class science, abundant talent, and a growing market. What remains is the courage to implement bold reforms.Capital-market innovation and regulatory modernization must be treated as national priorities to unlock the full potential of India’s biotech ecosystem.

With these reforms, India can evolve from being the “pharmacy of the world” to becoming the “lab of the world”, leading global biotech innovation rather than merely supplying it. Bold action today will secure India’s position as a front-runner in science, technology, and bio-based economic growth by 2047.